Arcturus Therapeutics (ARCT)
US Market

Arcturus Therapeutics (ARCT) Stock Price & Analysis


ARCT Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$11.70 - $31.41
Previous Close$20.64
Average Volume (3M)425.06K
Market Cap
Enterprise Value$247.09M
Total Cash (Recent Filing)$391.88M
Total Debt (Recent Filing)$90.87M
Price to Earnings (P/E)61.0
May 08, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.34
Shares Outstanding26,555,483
10 Day Avg. Volume269,076
30 Day Avg. Volume425,060
Standard Deviation0.32
Financial Highlights & Ratios
Price to Book (P/B)2.86
Price to Sales (P/S)9.01
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-3.20
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.20
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda14.85
Price Target Upside-5.42% Downside
Rating ConsensusHold
Number of Analyst Covering3



Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Arcturus Therapeutics’s price range in the past 12 months?
Arcturus Therapeutics lowest stock price was $11.70 and its highest was $31.41 in the past 12 months.
    What is Arcturus Therapeutics’s market cap?
    Currently, no data Available
    When is Arcturus Therapeutics’s upcoming earnings report date?
    Arcturus Therapeutics’s upcoming earnings report date is May 08, 2023 which is in 38 days.
      How were Arcturus Therapeutics’s earnings last quarter?
      Arcturus Therapeutics released its earnings results on Mar 28, 2023. The company reported $4.33 earnings per share for the quarter, beating the consensus estimate of -$1.72 by $6.05.
        Is Arcturus Therapeutics overvalued?
        According to Wall Street analysts Arcturus Therapeutics’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Arcturus Therapeutics pay dividends?
          Arcturus Therapeutics does not currently pay dividends.
          What is Arcturus Therapeutics’s EPS estimate?
          Arcturus Therapeutics’s EPS estimate is -$0.22.
            How many shares outstanding does Arcturus Therapeutics have?
            Arcturus Therapeutics has 26,555,483 shares outstanding.
              What happened to Arcturus Therapeutics’s price movement after its last earnings report?
              Arcturus Therapeutics reported an EPS of $4.33 in its last earnings report, beating expectations of -$1.72. Following the earnings report the stock price went up 30.129%.
                Which hedge fund is a major shareholder of Arcturus Therapeutics?
                Among the largest hedge funds holding Arcturus Therapeutics’s share is ARK Investment Management LLC. It holds Arcturus Therapeutics’s shares valued at 34M.


                  Arcturus Therapeutics Stock Smart Score

                  The Arcturus Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Arcturus Therapeutics

                  Arcturus Therapeutics Holdings, Inc. engages in the development of RNA therapeutics for treatment. It focuses on liver and respiratory diseases. Its pipeline include LUNAR-OTC, and LUNAR CF. The company was founded in 2013 and is headquartered in San Diego, CA.


                  Top 5 ETFs holding ARCT

                  Market Value
                  Smart Score
                  Fidelity Nasdaq Composite Index ETF
                  BMO MSCI Innovation Index ETF
                  Up to five ETFs with an Outperform Smart Score that hold ARCT. The ETFs are listed according to market value of ARCT within the ETF


                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  Inovio Pharmaceuticals
                  Eagle Pharmaceuticals

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis